It’s the 2nd buyout in as many days for the Abbott Park, Ill.-based healthcare giant, which yesterday said it plans to pay $5.8 billion for point-of-care diagnostics maker Alere.
Kalila, which is based in Campbell, Calif., won 510(k) clearance from FDA for the Vado device in April 2014, about 4 months after landing CE Mark approval in the European Union.
“Atrial fibrillation is a serious condition that increases the risk of stroke and causes severe symptoms in many patients, but remains undertreated today because current technologies have limited effectiveness,” electrophysiology GM Michael Pederson said in prepared remarks. “With this acquisition, Abbott gains a unique technology to expand our portfolio of tools for the treatment of atrial fibrillation and other heart rhythm disorders. We look forward to initiating the launch of this innovative sheath in the United States and Europe in the coming weeks.”